Dec 15, 2017   SOURCE: PR NewsWire

QIAGEN and Oxford Immunotec Settle Patent Infringement Lawsuit

GERMANTOWN, Maryland and HILDEN, Germany, December 15, 2017 /PRNewswire/ --

QIAGEN N.V. (NASDAQ: QGEN, Frankfurt Stock Exchange: QIA) and Oxford Immunotec Ltd. (NASDAQ: OXFD) announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN's QuantiFERON(R)-TB Gold and QuantiFERON(R)-TB Gold Plus products.

Under terms of the agreement, all pending claims between Oxford and QIAGEN and the co-defendants have been resolved. As part of the settlement, Oxford has granted QIAGEN a royalty-free, non-exclusive license that extends to all current and future customers of QuantiFERON-TB Gold and QuantiFERON-TB Gold Plus in exchange for a one-time, lump-sum payment of $27.5 million. The settlement includes general releases of all parties with no admissions of wrongdoing.

This agreement does not affect QIAGEN's adjusted EPS outlook for the fourth quarter and full-year 2017 since these one-time costs are excluded from adjusted results.  

Click here [https://corporate.qiagen.com/newsroom/press-releases/2017/20171215_QGEN_OXFD?sc_lang=en ] for the full press release https://corporate.qiagen.com/newsroom/press-releases/2017/20171215_QGEN_OXFD?sc_lang=en    

            Contacts: 


        QIAGEN 


        Investor Relations                      
        John Gilardi         
        +49-2103-29-11711   
        e-mail: ir@QIAGEN.com                          


        Public Relations  
        Dr. Thomas Theuringer  
        +49-2103-29-11826 
        e-mail: pr@QIAGEN.com

 

SOURCE QIAGEN